AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The National Eligibility-Entrance Test Super Speciality (NEET-SS) 2024 finally took place on March 29-30, 2025, following ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...